3 great income stocks I’d buy today

If you are looking for a base rate busting income these three FTSE 100 companies are a great place to start, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The earlier you start investing in income-generating stocks, the sooner those dividends will start piling up, and the richer you will ultimately be. Here are three great FTSE 100 income stocks that I would consider buying today. 

AstraZeneca

Before you put any money into AstraZeneca (LSE: AZN) you have to consider the small matter of its recent profit warning. The pharmaceuticals giant warned that cheaper generic versions of its cholesterol drug Crestor are continuing to eat into sales, triggering a 13% decline in revenues in the fourth quarter, with annual turnover falling 7% to £23bn.

The big hope now is that AstraZeneca can replenish its dwindling pipeline with a new generation of blockbusters. Chief executive Pascal Soriot knows this better than anybody, and next year we will discover whether his strategy of investing in a dozen or so new drugs will pay off.

Soriot is aiming to almost double company revenues to reach as much as $45bn by 2023 and says AstraZeneca is rapidly approaching the “inflection point“, with 12 drugs in the final stage of development, including cancer and asthma treatments. If they succeed, the rewards will flow. You get a healthy 4.73% yield while you wait for the answer, but AstraZeneca may be too risky for some.

National Grid

Utility company National Grid (LSE: NG) offers a similar-sized yield of 4.52%, but with fewer risks, as it is a heavily regulated industry offering a basic service to millions of customers in the UK and north-eastern US. This assures relatively steady earnings and cash flows.

This gives management the confidence to pledge to increase its dividend each year in line with the retail price index, which stood at 2.5% in December. Investors also benefit from share buybacks and special dividends, with the company recently announcing plans to sell a majority stake in its gas distribution business and return £4bn from the sale to shareholders. Share price growth has been steady too, up 50% in five years, although it has wobbled lightly. This remains one of my favourite income stocks.

Persimmon

Housebuilders have had a bumpy ride since Brexit, Persimmon (LSE: PSN) included. But it has recovered lately, rising 17% in the last six months as the UK economy, population and house prices have continued to grow.

The housing crisis is one of the biggest problems facing Britain and few believe the government has the answers, following the publication of last week’s Housing White Paper, widely seen as a damp squib. This was seen as good news for housebuilders, as the clamour for property looks set to continue. Persimmon rose 3.47% on Wednesday as a result, faster than any housebuilder.

Perhaps Brexit will slow population growth, perhaps not. Perhaps interest rates will rise spark a crash, but I doubt it. House price growth is certainly slowing, falling to 5.7% a year in January, down from a high of 10% last March, Halifax says. But I am still backing UK property, a scarce resource, especially with Persimmon trading at just 11.5 times earnings and yielding 5.57%, which is more than 22 times base rate.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

At a 27-year low, will this once-grand FTSE 100 giant be relegated to the FTSE 250 soon?

After a tough year, WPP’s share price has plummeted. But with AI adoption and new leadership, could the advertising giant…

Read more »

estate agent welcoming a couple to house viewing
Investing Articles

With 118% earnings growth, analysts think this value share could soar 70% in the coming 12 months!

Mark Hartley takes a closer look at a small-cap British value share that's been tipped to rally in the coming…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

Is Diageo’s share price now the FTSE 100’s best bargain?

Diageo's share price has tumbled to its lowest level in around a decade. Does this make the FTSE firm a…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

I asked ChatGPT for a portfolio of FTSE 250 growth shares to buy. Can I beat it?

In a battle of man vesus machine, can our writer Royston Wild come out on top against ChatGPT with his…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Rotating out of technology? Consider the Jet2 share price

The Jet2 share price has pulled right back in recent months while technology stocks have pushed to new highs. Dr…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

£20,000 invested in Rolls-Royce shares 1 year ago is currently worth…

Dr James Fox takes a closer look at Rolls-Royce shares after another incredible year of growth for the British aerospace…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

How big does a Stocks and Shares ISA need to be to target a £1k monthly passive income?

Christopher Ruane explains how a Stocks and Shares ISA can be used as part of a strategy to try and…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

As software stocks get slaughtered are these S&P 500 names next to crash?

AI's been sending some of the S&P 500’s tech stocks crashing. But Stephen Wright thinks some companies will be more…

Read more »